15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride doesn't affect erections much, but may decrease libido in men.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
27 citations
,
July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology” The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
September 2004 in “Inpharma Weekly”
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
September 2016 in “Reactions Weekly” Dutasteride and finasteride don't raise erectile dysfunction risk.
15 citations
,
January 2017 in “Experimental Neurology” Finasteride reduces movement issues in Parkinson's disease rats.
1 citations
,
August 2024 in “Expert Opinion on Drug Safety” Finasteride is most linked to drug-induced erectile dysfunction.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
April 2017 in “Austin Journal of Cancer and Clinical Research” 5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
33 citations
,
April 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
1 citations
,
November 2024 in “Archives of Dermatological Research”
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
June 2026 in “Frontiers in Medicine” 5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.
March 2005 in “Current Prostate Reports” April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
The document's conclusion cannot be provided because the document is not available or cannot be read.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
July 2025 in “Journal of Investigative Dermatology” January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
1 citations
,
January 2015 in “Sexual Medicine Reviews” Current treatments for recurrent ischemic priapism are not well-defined and need more research.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.